Investor Overview

Corporate Profile

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications including type 2 diabetes and other chronic conditions.

Corporate Presentation
Webcasts
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024 , and
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C. , Aug.
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
HIGH POINT, N.C. , July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
Cadisegliatin   is   a   potential   first-in-class   oral   liver   selective   glucokinase   activator   for   T1D,   which   has   been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin   has   been   dosed   in   over   500   subjects   to   date,   including   300  
View HTML
PDF Version
More >>

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Minimum 15 minutes delayed. Source:

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)  
Volume
Data as of

Minimum 15 minutes delayed. Source: